Apellis Pharmaceuticals Inc [APLS] stock prices are down -1.18% to $18.39 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The APLS shares have gain 3.55% over the last week, with a monthly amount glided 5.45%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Apellis Pharmaceuticals Inc [NASDAQ: APLS] stock has seen the most recent analyst activity on May 09, 2025, when Raymond James downgraded its rating to a Outperform but kept the price target unchanged to $52 for it. Previously, BofA Securities downgraded its rating to Neutral on May 09, 2025, and kept the price target unchanged to $23. On April 29, 2025, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $44 on the stock. Goldman downgraded its rating to a Neutral but stick to its price target of $36 on December 17, 2024. Morgan Stanley initiated its recommendation with a Equal-Weight and recommended $31 as its price target on November 21, 2024. RBC Capital Mkts started tracking with a Sector Perform rating for this stock on October 25, 2024, and assigned it a price target of $25. In a note dated October 16, 2024, William Blair initiated an Outperform rating.
The stock price of Apellis Pharmaceuticals Inc [APLS] has been fluctuating between $16.10 and $42.47 over the past year. Currently, Wall Street analysts expect the stock to reach $74.5 within the next 12 months. Apellis Pharmaceuticals Inc [NASDAQ: APLS] shares were valued at $18.39 at the most recent close of the market. An investor can expect a potential return of 305.11% based on the average APLS price forecast.
Analyzing the APLS fundamentals
The Apellis Pharmaceuticals Inc [NASDAQ:APLS] reported sales of 775.84M for trailing twelve months, representing a drop of -3.21%. Gross Profit Margin for this corporation currently stands at 0.83% with Operating Profit Margin at -0.24%, Pretax Profit Margin comes in at -0.29%, and Net Profit Margin reading is -0.29%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -1.0 and Total Capital is -0.3. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of2.86.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 18.09 points at the first support level, and at 17.80 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.65, and for the 2nd resistance point, it is at 18.91.
Ratios To Look Out For
It’s worth pointing out that Apellis Pharmaceuticals Inc [NASDAQ:APLS]’s Current Ratio is 4.08. As well, the Quick Ratio is 3.62, while the Cash Ratio is 2.01. Considering the valuation of this stock, the price to sales ratio is 2.98, the price to book ratio is 14.07.
Transactions by insiders
Recent insider trading involved Watson David O., General Counsel, that happened on Jun 16 ’25 when 5000.0 shares were sold. Officer, Watson David O. completed a deal on Jun 16 ’25 to buy 5000.0 shares. Meanwhile, Former Officer Townsend Adam J. bought 0.22 million shares on May 12 ’25.
